Valuation: Seres Therapeutics, Inc.

Market Cap 59.17M 51.84M 47.8M 44.17M 83.74M 5.64B 85.14M 571M 224M 2.78B 222M 217M 9.57B P/E 2026 *
-0.81x
P/E 2027 * -0.93x
Enterprise Value 59.17M 51.84M 47.8M 44.17M 83.74M 5.64B 85.14M 571M 224M 2.78B 222M 217M 9.57B EV / Sales 2026 *
4.6x
EV / Sales 2027 * 165x
Free-Float
88.22%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Seres Therapeutics, Inc.

1 day-9.35%
1 week-21.06%
Current month-22.56%
1 month-5.86%
3 months-26.56%
6 months-60.96%
Current year-58.94%
1 week 6.02
Extreme 6.025
8.25
1 month 5.31
Extreme 5.31
8.25
Current year 5.31
Extreme 5.31
16.42
1 year 5.31
Extreme 5.31
29.98
3 years 5.31
Extreme 5.31
105.8
5 years 5.31
Extreme 5.31
437.8
10 years 5.31
Extreme 5.31
770
Manager TitleAgeSince
Chief Executive Officer 70 01/03/2026
Chief Executive Officer 58 31/07/2025
President 51 01/03/2026
Director TitleAgeSince
Chairman 70 01/03/2026
Director/Board Member 50 14/01/2019
Director/Board Member 80 31/03/2015
Date Insider Type Main position Quantity % Market Cap.
07-07Free

Chief Executive Officer

50,000 0.5163%
07-07Free

Director

6,500 0.0671%
07-07Free

Chief Operating Officer

18,750 0.1936%
Change 5-day change 1-year change 3-year change Capi.($)
-9.35%-21.06%-50.53%-93.65% 59.17M
-4.14%-8.06%+57.35%+117.24% 54.63B
+1.84%-0.66%+75.79%+93.87% 54.88B
-2.24%+3.59%+19.60%+466.72% 25.06B
-1.60%-6.21%-19.69%-14.84% 23.14B
+2.43%+1.06%+47.70%-0.11% 19.88B
-3.19%0.00%+33.99%-26.87% 17.55B
-6.84%+2.18%+195.12%+357.18% 16.5B
-1.05%+1.16%+25.08%+196.28% 14.2B
+8.74%+3.51%+53.81% - 15.36B
Average -1.54%-1.54%+43.82%+121.76% 24.13B
Weighted average by Cap. -0.91%-1.46%+55.02%+137.72%

Financials

2026 *2027 *
Net sales 12.86M 11.27M 10.39M 9.6M 18.2M 1.23B 18.5M 124M 48.67M 604M 48.27M 47.22M 2.08B 358K 314K 289K 267K 507K 34.14M 515K 3.45M 1.36M 16.82M 1.34M 1.31M 57.88M
Net income -70.97M -62.18M -57.33M -52.97M -100M -6.77B -102M -685M -269M -3.33B -266M -261M -11.47B -99.82M -87.46M -80.64M -74.51M -141M -9.52B -144M -963M -378M -4.69B -375M -367M -16.14B
Net Debt - -
Logo Seres Therapeutics, Inc.
Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. It is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.
Employees
66
Date Price Change Volume
10/07/26 US$6.110 -9.35% 154,449
09/07/26 US$6.740 -5.60% 121,957
08/07/26 US$7.140 -12.29% 258,095
07/07/26 US$8.140 +5.58% 98,987
06/07/26 US$7.710 -0.39% 31,504
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
6.110USD
Average target price
17.00USD
Spread / Average Target
+178.23%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MCRB Stock